Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 49

ARISTOTLE: Major Bleeding

Again the corollary to anticoagulant therapy is risk of bleeding, and the Figure shows the curves for major bleeding events with apixaban.[99] Apixaban was clearly superior to warfarin for this result, with a risk reduction of 31% (p<0.001).  This stands in contrast to rivaroxaban and dabigatran, where the risk of major bleeding was similar to that with warfarin.

 Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[99] Granger CB, Alexander JH, McMurray JV, et al; the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

Unable to display view foot.php file not found.